Market Research Logo

Urinary Incontinence - Pipeline Review, H2 2018

Urinary Incontinence - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H2 2018, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 6, 1, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Urinary Incontinence - Overview
Urinary Incontinence - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Urinary Incontinence - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Urinary Incontinence - Companies Involved in Therapeutics Development
Allergan Plc
Beech Tree Labs Inc
Crystec Ltd
Fate Therapeutics Inc
FemmePharma Global Healthcare Inc
GTx Inc
Innovacell Biotechnologie AG
Ipsen SA
Mylan NV
Pfizer Inc
Saniona AB
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Taris Biomedical LLC
Urinary Incontinence - Drug Profiles
abobotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTL-hs - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Gastrointestinal Disorders, Ischemic Heart Failure and Urological Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enobosarm - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gtx-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICES-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
litoxetine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prof-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate kV7 for Epilepsy, Pain and Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolterodine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trospium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Urinary Incontinence - Dormant Projects
Urinary Incontinence - Discontinued Products
Urinary Incontinence - Product Development Milestones
Featured News & Press Releases
May 18, 2018: GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting
Apr 16, 2018: GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting
Apr 09, 2018: GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
Mar 05, 2018: GTx Announced New Data Demonstrating Enobosarm's Potential to Treat Stress Urinary Incontinence at SUFU
Feb 22, 2018: GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence Accepted for Podium Presentation at SUFU
Jan 11, 2018: Sleep quality improves with help of incontinence drug
Sep 21, 2017: GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City
Sep 13, 2017: GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
Jun 12, 2017: GTx Announces Positive Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
May 11, 2017: GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting
Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence
May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego
Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Urinary Incontinence, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Urinary Incontinence - Pipeline by Allergan Plc, H2 2018
Urinary Incontinence - Pipeline by Beech Tree Labs Inc, H2 2018
Urinary Incontinence - Pipeline by Crystec Ltd, H2 2018
Urinary Incontinence - Pipeline by Fate Therapeutics Inc, H2 2018
Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, H2 2018
Urinary Incontinence - Pipeline by GTx Inc, H2 2018
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2018
Urinary Incontinence - Pipeline by Ipsen SA, H2 2018
Urinary Incontinence - Pipeline by Mylan NV, H2 2018
Urinary Incontinence - Pipeline by Pfizer Inc, H2 2018
Urinary Incontinence - Pipeline by Saniona AB, H2 2018
Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018
Urinary Incontinence - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Urinary Incontinence - Pipeline by Taris Biomedical LLC, H2 2018
Urinary Incontinence - Dormant Projects, H2 2018
Urinary Incontinence - Dormant Projects, H2 2018 (Contd..1), H2 2018
Urinary Incontinence - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Urinary Incontinence, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report